Selective IL-1 activity on CD8(+) T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

BACKGROUND: Clinical success of therapeutic cancer vaccines depends on the ability to mount strong and durable antitumor T cell responses. To achieve this, potent cellular adjuvants are highly needed. Interleukin-1β (IL-1β) acts on CD8(+) T cells and promotes their expansion and effector differentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Den Eeckhout, Bram, Huyghe, Leander, Van Lint, Sandra, Burg, Elianne, Plaisance, Stéphane, Peelman, Frank, Cauwels, Anje, Uzé, Gilles, Kley, Niko, Gerlo, Sarah, Tavernier, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593706/
https://www.ncbi.nlm.nih.gov/pubmed/34772757
http://dx.doi.org/10.1136/jitc-2021-003293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593706/
https://www.ncbi.nlm.nih.gov/pubmed/34772757
http://dx.doi.org/10.1136/jitc-2021-003293

Ejemplares similares